The FDA and Reglan
The Food and Drug Administration regulates the pharmaceutical industry in the United States, meaning that this agency is responsible for providing warnings when a drug may prove dangerous. In the case of Reglan, which has been directly linked to the development of tardive dyskinesia and similar muscle disorders, the FDA has given the drug the strongest warning possible. Known as the black box warning, this label is meant to limit the drug’s use as a heartburn treatment.
For additional information concerning your legal options if you have been diagnosed with tardive dyskinesia from Reglan use, contact the Reglan lawyers of Williams Kherkher by calling 800-761-3187 today.
Reglan and the Black Box Warning
The FDA applied the black box warning for drugs containing metoclopramide, which includes Reglan in any of its forms. This drug increases muscle contractions in the upper digestive system, helping to process food at a faster rate. As a result, the acid responsible for heartburn stays out of the esophagus. However, this drug may affect the body’s muscles in unintended ways. The FDA has warned against Reglan use in the following situations:
- High dosage treatments
- Long-term treatments
- Chronic treatments
The Food and Drug Administration has clearly warned that this drug should be used with short, low-dose exposure, if at all. Tardive dyskinesia typically cannot be reversed after it develops, leaving sufferers without full muscle control over their body.
Contact Us
If you have developed a neuromuscular disorder because of Reglan use, you may be eligible to pursue legal action. This drug warrants the FDA’s strongest possible warning and is not safe for use by certain patients. To learn more about your legal options, contact the Reglan attorneys of Williams Kherkher today at 800-761-3187.
